Cardiogenic shock remains a challenging clinical syndrome characterized by critically impaired cardiac output, systemic hypoperfusion, and high mortality rates. Although numerous diagnostic strategies and therapeutic interventions have emerged, patient outcomes continue to be suboptimal, highlighting the need for deeper integration between basic research findings and practical clinical management strategies. Recent studies increasingly point towards the significance of valvular dysfunction, especially tricuspid regurgitation, in influencing the onset, progression, and prognosis of cardiogenic shock. Despite being historically overlooked, recent evidence links tricuspid valve dysfunction intimately with the pathophysiology of right ventricular failure and systemic congestion common in cardiogenic shock, emphasizing the urgent need to explore diagnostic and therapeutic options targeting the tricuspid valve in these critically ill patients.
The aim of this Research Topic is to bridge the gap between basic laboratory insights and clinical management strategies, focusing specifically on elucidating the relationship between the tricuspid valve function and cardiogenic shock progression. We seek to unravel how diagnostic advancements, targeted therapies, and improved management strategies involving tricuspid valve assessment and treatment may lead to better patient outcomes, more personalized care, and reduced mortality.
To offer comprehensive insights into this evolving research domain, we welcome submissions exploring, but not limited to, the following themes:
• Pathophysiological mechanisms: Investigating cellular and molecular links between tricuspid valve dysfunction, right ventricular impairment, and cardiogenic shock progression.
• Diagnostic advances: Emerging imaging modalities, biomarkers, and functional assessments for early and accurate identification of tricuspid valve involvement in cardiogenic shock.
• Therapeutic innovations: Assessment of novel pharmacological interventions, transcatheter techniques, and surgical approaches specifically addressing tricuspid valve dysfunction in cardiogenic shock management.
• Clinical outcomes and management strategies: Evaluating best practices in the integration of tricuspid-targeted therapies in cardiogenic shock patient care pathways.
• Translational research: Bridging preclinical studies examining potential targeted treatments to clinical trials and therapeutic innovations in patients with cardiogenic shock.
Through this integrative approach, we aim to catalyze new advances and provide clarity on the pivotal role the tricuspid valve plays in cardiogenic shock management, ultimately promoting improved therapies, patient-specific interventions, and superior clinical outcomes
Keywords: Cardiogenic Shock, Cardiac Intensive Care, Molecular Mechanisms, Biomarkers, Diagnostic Innovations, Pharmacological Treatments, Mechanical Support Devices, Patient Outcomes, Translational Research, Case Studies
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
